The effect of comt inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations

European Neurology

Volumn 38, Issue 1, 1997, Pages 59-67

  Jorga, Karin ^a   Fotteler, Bärbel ^a   Schmitt, Monique ^a   Nielsen, Thorkild ^a   Zürcher, Gerhard ^a   Aitken, John ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

COMT inhibition; Levodopa benserazide; Parkinson s disease; Pharmacokinetics; Tolcapone

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; ERYTHROCYTE ENZYME; TOLCAPONE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TIME; VERTIGO;

ADJUVANTS, PHARMACEUTIC; ADULT; ANTIPARKINSON AGENTS; BENSERAZIDE; BENZOPHENONES; BIOLOGICAL AVAILABILITY; CATECHOL O-METHYLTRANSFERASE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; LEVODOPA; MALE; NITROPHENOLS; REFERENCE VALUES;

EID: 0030845466     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000112904     Document Type: Article

References (14)

1. Caine DB: Treatment of Parkinson’s disease. N Engl J Med 1993;329:1021-1027.
2. LeWitt PA: Treatment strategies for extension of levodopa effect. Neurol Clin 1992:10:511-526.
3. Quinn N, Parkes JD, Marsden CD: Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984;34: 1131-1136.
4. Contin M, Riva R, Albani F, Baruzzi A: Pharmacokinetic optimisation in the treatment of Parkinson’s disease. Clin Pharmacokinet 1996: 30:463-481
5. Dingemanse J. Jorga KM, Schmitt M, Gieschke R. Fotteler B. Zürcher G, Da Prada M, van Brummelen P: Integrated pharmacokinetics and pharmacodynamics of the novel ca-techol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-517.
6. Jorga K, Dingemanse J, Fotteler B, Zürcher G: Pharmacokinetics-pharmacodynamics of a novel COMT inhibitor during multiple dosing regimens. Clin Pharmacol Ther 1993:53:11-40.
7. Zürcher G, Dingemanse J, Da Prada M: Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv Neurol 1993;60:641-647.
8. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M. van Brummelen P: Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995:40:253-262.
9. Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T, van Brummelen P: Multi-ple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996:50: 47-55.
10. Zürcher G, Da Prada M, Dingemanse J: Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans. Biomed Chromatogr 1996; 10:32-36.
11. Nohta H, Mona S, Ohkura Y, Yoo BT: Assay for catechol-O-methyltransferase in erythrocytes using a new fiuorogenic substrate, 2-(3.4-dihydroxyphenyl)naphtol[1,2-d]thiazole. J Chromatogr 1984;308:93-100.
12. Zürcher G, Da Prada M: Simple automated high-performance liquid chromatographic column-switching technique for the measurement of dopa and 3-0-methyldopa in plasma. J Chromatogr 1990;530:253-262.
13. Kurth MC, Adler CH, Saint Hilaire M, Singer C, Waters CH, LeWitt P, Chemik DA, Dorflinger EE, Yoo K, the Tolcapone Fluctuator Study Group I: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinsons’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
14. Waters CH, Kurth M, Bailey P, Shulman L, LeWitt P, Dorfiinger E, Deptula D, Pedder S: Tolcapone in stable Parkinson’s disease: Efficacy and safety of long-term treatment. Neurology, in press.